Shingrix Can Be Safely Given to Patients on HIV or Hepatitis Medications
Yes, the recombinant zoster vaccine (Shingrix/RZV) can and should be administered to patients receiving antiretroviral therapy for HIV or hepatitis medications, as it is a non-replicating subunit vaccine that is safe in immunocompromised populations.
Key Distinction: Shingrix vs. Live Zoster Vaccine
The critical point is that Shingrix (RZV) is NOT a live vaccine - it is a recombinant subunit vaccine containing only varicella-zoster virus glycoprotein E with adjuvant 1, 2. This makes it fundamentally different from the older live-attenuated zoster vaccine (Zostavax), which was contraindicated in highly immunocompromised patients 3.
Specific Recommendations for HIV Patients
For patients on HIV antiretroviral therapy:
- RZV is recommended for HIV-infected adults aged ≥19 years who are or will be immunocompromised 2
- The vaccine has demonstrated safety and immunogenicity in HIV-infected adults on stable antiretroviral therapy 3
- Optimal timing: Administer when CD4 count is ≥200 cells/mm³ with controlled viral load 4
- A phase 1/2 study of 123 HIV-infected adults (including those with CD4 counts 50-199 cells/mm³) showed RZV was immunogenic with a clinically acceptable safety profile, with no sustained impact on HIV viral load or CD4 counts 4
- Recent real-world data from 223 HIV patients vaccinated with RZV showed only 8.97% post-vaccination herpes zoster reactivation with complete resolution of postherpetic neuralgia 5
Hepatitis Patients
For patients on hepatitis medications:
- There are no contraindications to RZV administration in patients receiving hepatitis treatment 1
- Hepatitis medications do not typically cause the degree of immunosuppression that would preclude vaccination
- Hepatic comorbidities were associated with slightly higher HZ recurrence risk (OR 3.67) in one study, but this supports vaccination rather than contraindicates it 5
Safety Profile in Immunocompromised Populations
A comprehensive pooled analysis of 1,587 immunocompromised adults (including transplant recipients, patients with hematologic malignancies, solid tumors, and HIV) demonstrated 6:
- Solicited adverse events were mostly mild-to-moderate and resolved within 3 days (median)
- Unsolicited adverse events and serious adverse events were comparable between RZV and placebo groups
- No safety concerns were identified across diverse immunocompromised populations
- The vaccine has a clinically acceptable safety profile with a favorable benefit-risk profile 6
Practical Administration Guidelines
Dosing schedule:
- Two 0.5 mL doses administered intramuscularly at 0 and 2 months (can extend to 0 and 6 months if needed) 1
- Do not delay - can be given concomitantly with other vaccines including influenza, pneumococcal (PNEUMOVAX 23, PREVNAR 13), and Tdap 1
Common pitfall to avoid:
- Do NOT confuse Shingrix with the old live-attenuated Zostavax - they have completely different safety profiles in immunocompromised patients 3, 2
- Live vaccines ARE contraindicated in HIV patients with CD4 <200 cells/µL or uncontrolled HIV, but Shingrix is NOT a live vaccine 7
Efficacy Data
The vaccine demonstrates 1:
- 91.3% efficacy against herpes zoster in adults ≥70 years
- 88.8% efficacy against postherpetic neuralgia
- Protection persists with incidence rates remaining lower than placebo groups even at median 11.4 years post-vaccination 1
Bottom line: Shingrix is specifically designed for and approved in immunocompromised populations, making it the ideal choice for patients on HIV or hepatitis medications 2, 8.